Upadacitinib (Rinvoq, AbbVie) improves Type 1 inflammation markers and circulating melanocyte-associated proteins in vitiligo. John E. Harris, MD, PhD, the Founding Director of the Vitiligo Clinic and Research Center, Founding Director of the Autoimmune Therapeutics Institute, and Professor and Chair in the Department of Dermatology at UMass Chan Medical School in Worcester, MA, reviews the Phase 2 data, which he presented at the 2025 American Academy of Dermatology Annual Meeting. Dr. Harris also discusses the unmet needs for patients with vitiligo and his hopes for the future.
